Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract
Interventions: DRUG: Lenvatinib|DRUG: Capecitabine
Sponsor: M.D. Anderson Cancer Center
Collaborators: Eisai Inc.